Diabetes mellitus due to underlying condition with ketoacidosis without coma
Methodology & AI Transparency ⓘ
Diabetes mellitus due to underlying condition with ketoacidosis without coma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Diabetes mellitus due to underlying condition with ketoacidosis without coma—coded clinically as E08.10 across Diabetes & Glucose guidelines—combines peripheral monofilament testing [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] with structured follow-up of Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] (4.8% – 5.6% (< 6.5% clinical target) (E08.10)).
- 2 Real-world patient consensus: Clinical coding for Diabetes mellitus due to underlying condition with ketoacidosis without coma uses ICD-10 E08.10 across Diabetes & Glucose specialty care.
- 3 Typical cash cost range: Workup highlights for Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10): peripheral monofilament testing [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10].
- 4 Top reported side effects / signs: Key Diabetes & Glucose biomarkers for Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10): CGM Time-in-Range (70–140 in Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10: mg/dL)) & Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] (4.8% – 5.6% (< 6.5% clinical target) (E08.10)).
Ask our AI Specialists anything about Diabetes mellitus due to underlying condition with ketoacidosis without coma
What Is Diabetes mellitus due to underlying condition with ketoacidosis without coma?
Diabetes mellitus due to underlying condition with ketoacidosis without coma—coded clinically as E08.10 across Diabetes & Glucose guidelines—combines peripheral monofilament testing [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] with structured follow-up of Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] (4.8% – 5.6% (< 6.5% clinical target) (E08.10)).
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10, Diabetes & Glucose) reflects advanced glycation end-product in Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10: microvascular injury). longitudinal control is benchmarked via CGM Time-in-Range (70–140 in Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10: mg/dL)).
Common Symptoms & Clinical Signs
- • Presentation of Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10): elevated fasting blood in Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10: glucose or post-meal)
- • Secondary Diabetes mellitus due to underlying condition with ketoacidosis without coma clinical sign: increased thirst [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10]
- • Symptom flares in Diabetes mellitus due to underlying condition with ketoacidosis without coma correlating with CGM Time-in-Range (70–140 in Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10: mg/dL)) deviation outside > 85% (E08.10)
- • Functional diabetes & glucose impact requiring peripheral monofilament testing [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] evaluation (E08.10)
Diabetes mellitus due to underlying condition with ketoacidosis without coma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E08.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Diabetes mellitus due to underlying condition with ketoacidosis without coma (E08.10: mg/dL)) | > 85% (E08.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] | 4.8% – 5.6% (< 6.5% clinical target) (E08.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetes mellitus due to underlying condition with ketoacidosis without coma E08.10] | 75 – 95 mg/dL (E08.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetes mellitus due to underlying condition with ketoacidosis without coma
Treatment selection for Diabetes mellitus due to underlying condition with ketoacidosis without coma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetes mellitus due to underlying condition with ketoacidosis without coma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Diabetes mellitus due to underlying condition with ketoacidosis without coma Patient Community & “People Like Me” Threads
Filter Diabetes mellitus due to underlying condition with ketoacidosis without coma community threads and patient logs by age, biological sex, dosage, and treatment duration.